Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.

Saved in:
Bibliographic Details
Title: Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
Authors: Taieb J; Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France; Centre de Recherche des Cordeliers, INSERM, CNRS, Université Paris-Cité, Sorbonne Université, USPC, Equipe Labellisée Ligue Nationale Contre le Cancer, SIRIC CARPEM, Paris, France. Electronic address: jtaieb75@gmail.com., Modest DP; Department of Hematology, Oncology and Cancer Immunology (CVK), Charité-Universitaetsmedizin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Fakih M; City of Hope Comprehensive Cancer Center, Duarte, USA., Ciardiello F; Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy., Van Cutsem E; University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium., Elez E; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain., Gravalos C; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain., Bragagnoli AC; Fundacao Pio Xii Hospital Cancer De Barretos, Barretos, Brazil., Barboux V; Servier International Research Institute, Suresnes, France., Roby L; Servier International Research Institute, Suresnes, France., Amellal N; Servier International Research Institute, Suresnes, France., Prager GW; Medical University Vienna, Vienna, Austria.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Sep 09; Vol. 227, pp. 115644. Date of Electronic Publication: 2025 Jul 12.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115644